Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin for diarrhea-predominant irritable bowel syndrome
IRCT20141201020178N12Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of rifaximin in Diarrhea-predominant irritable bowel syndrome (IBS-D), sponsored by Iran University of Medical Sciences. Started Jul 2023; status: completed.
02
Drugs
rifaximin
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on IRCT20141201020178N12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20141201020178N12.